MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005)
Status:
Recruiting
Trial end date:
2025-02-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy
of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer
therapies in participants with selected advanced solid tumors. The primary hypothesis is that
pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of
objective response rate or progression-free survival in participants with cervical cancer.